ADHD: Melatonin er både sikkert, effektivt og anbefalet.

Jævnligt ser vi overskrifterne i aviserne om at ‘danske børns forbrug af sovemedicin er eksploderet’ og lignende. Men i sandhed skyldes udviklingen i forbruget af Melatonin, der ikke er sovemedicin i øvrigt, at flere og flere har forstået, at ADHD medfører søvnforstyrrelser hos mange, og til disse viser videnskabelig evidens, at Melatonin er både sikkert, effektivt og anbefalet til behandling af søvnforstyrrelser ved både ADHD og Autisme.

Continue Reading →

Storebø et al.: How’d you like them Apples?

Since 2015, Storebø et al. have tried to vilify Methylphenidate, by creating doubt around the validity of the scientific evidence which, for more than 50 years, have told us, that Methylphenidate was safe, effective, and had few serious side-effects. It have caused tremendous harm to patients, all over the world, as well as taken time, money and focus from ‘real’ science. In this article, I ask Storebø et al. (after advice from Cochrane Institute), to clarify their conclusions in their research, and ask them to explain why their science is so ‘bias-fixated’.

Continue Reading →

ADHD: Kan man vokse fra ADHD?

I mange år mente man, at ADHD var en børnesygdom, og at man voksede fra den. Selvom vi har vidst at det ikke er korrekt, i mere end 10 år, så går folk fortsat rundt og fortæller hinanden, at “jo jo – det kan man da'” … Derfor har vi lavet en artikel om hvorfor det ikke er korrekt og ikke mindst – hvorfor det ikke er sandt!

Continue Reading →

ADHD: Storebø accused of false results and inadequate conclusions

In a thorough and evidence-based commentary on Storebø OJ. et al.’s 2015 Cochrane System Review, Dr. Dr. Tobias Banaschewski et al. pull the Cochrane System Review apart, inch by inch, and finally concludes, that Storebø’s work is based on false results and inadequate conclusions, under the title: Trust, but verify!

Continue Reading →

ADHD: The Jury Is In On Storebø – You’re Done!

After 4 years of bickering and with no useful results, Storebø OJ. and Simonsen E. et al. have just wasted God knows how much of our sparse research funds on … what!? … Nothing! … We call for a scientific enquiry into their agenda!

Continue Reading →

ADHD: Psykoser pga ADHD medicin skyldes komorbid Skizofreni eller Bipolar lidelse, ikke ADHD-medicin

Familiel højrisiko (FHR) af skizofreni (FHR-SZ) og bipolar lidelse (FHR-BP) er yderst signifikant i komorbiditet til ADHD. En ny undersøgelse af 522 – 7-årige – viser, at 20,9% af afkom med FHR-SZ og 9,3% af afkom med FHR-BP, også lider af ADHD. Dette har vigtige konsekvenser for lægebehandling med ADHD medicin på grund af den øgede risiko for at udvikle psykose som følge af ADHD-medicinering.

Continue Reading →

Very low risk of Psychosis due to ADHD medication

Great news! New study published on March 21, 2019 provides yet more evidence to safety and efficacy of psychostimulants like Ritalin (Methylphenidate) and Adderall (Amphetamine). The study examined 337,919 adolescents and young adults who received a prescription for a stimulant for ADHD. The results showed that among adolescents and young adults with ADHD who were receiving prescription stimulants, new-onset psychosis occurred in approximately 1 in 660 patients.

Continue Reading →

ADHD: Methylphenidate (Ritalin etc.) is safe and effective for 99% of all people

Great news! In a 2018 review by Storebø et al. it was proven that Methylphenidate was safe and effetive for more than 92.7% of the 2,207.751 participants in their review of 260 studies. The review also showed that 99% did not have any serious adverse events (serious side effects), and 98,8% did not withdraw from using Methylphenidate due to any serious adverse events, and 92.7% did not withdraw from any adverse events.

Continue Reading →

Nocebo, ADHD and Cochrane

For the past few years now, I’ve been following the debate on the quality of the studies of ADHD medication, and it strikes me that there seems to be an anti-ADHD medications agenda being pushed by The Cochrane Institute and in particular Ole Jakob Storebø, Ph.D.. We ask them, why?

Continue Reading →